Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Feb 19, 2021 10:17am
336 Views
Post# 32608700

RE:RE:Why i am not accumulating

RE:RE:Why i am not accumulating
Beanie28 wrote:
go away


Ya - I've heard it all before.
No one knows which way this goes but the odds are on it going up in the near-term.
Cash in the bank means we are in a stronger position - for negotiating and as a company.

If I'm an institutional investor and I look at this balance sheet ... much stronger now.

Keep the exciting news flowing (still lots availabe) and we're making our way to a US exchange.

Remember ... keep the list in mind ...
1.  P3 design updates (including all pre-P3 animal study results)
2.  FDA meeting
3.  -352 updates
4.  -340 updates (could be related to a COvID update as well)
5.  fast iteration drug development updates (betting on an Alzheimer's/Parkinsons or a brain cell drug carrier next)
6.  US exchange
7.  amagamation
8.  collaborations (heck ... if drug development is going to improve ... might as well find partners to help push some of these new drugs to the finish line faster - some with lots of cash - that collaboration could end up being a take-out partner one day.
9.  partnerships
10. sale of Citagenix
11. all the others I missed on this list

So many possible angles and I wouldn't bet that we stand still ... not with cash in the bank and a technical advantage in "fast iterations" for gaseous mediator development.  Kings of a whole new field of medicine ???????

Cheers All !

<< Previous
Bullboard Posts
Next >>